Business
Development

Our Philosophy to Partnering

Mirati is seeking collaboration opportunities for novel approaches to oncology with assets that target kinase inhibitors and epigenetic targets.

Currently, worldwide rights to all pipeline programs are owned by Mirati Therapeutics except certain Asian rights for sitravatinib, where the program is partnered with BeiGene.

Collaboration Inquiries

Jessica M. Corson, MBA
Email: bd@Mirati.com
Phone: 858-332-3410

Our Commercial Partnership in Asia

Beigene Logo

In January 2018, Mirati and Beigene announced an exclusive license agreement for the development, manufacturing and commercialization of Mirati’s sitravatinib in Asia (excluding Japan), Australia, and New Zealand. Mirati retained exclusive rights for the development, manufacturing and commercialization of sitravatinib for the rest of world.

Mirati is eligible to receive milestone payments based upon the achievement of certain development, regulatory and sales milestones as well as significant royalties on future sales of sitravatinib in the licensed territory.

Our Clinical Collaborations

Bristol-Myers Squibb

In January 2019, Mirati and Bristol-Myers Squibb Company (BMY) announced a clinical collaboration to evaluate the combination of sitravatinib and nivolumab (OPDIVO®), in a Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.

Under the terms of the collaboration, Mirati will sponsor and fund the clinical trial and Bristol-Myers Squibb will provide nivolumab at no cost. Mirati maintains global development and commercial rights to sitravatinib outside of certain Asian territories, where it is partnered with BeiGene, and is free to develop the program in combination with other agents.

In July 2019, Mirati and Novartis (NVS) announced a clinical collaboration agreement to evaluate the combination of MRTX849, Mirati’s investigational KRAS G12C inhibitor and TNO155, Novartis’ investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations.

Under terms of the non-exclusive collaboration, Mirati will sponsor the trial and Novartis and Mirati will jointly oversee and share the costs of clinical development activities for the combined therapy. Novartis will provide TNO155 at no cost.